|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Stathmin protein expression was often more intense in the peripheral regions of tumour trabeculae, tumour borders, and portal vein tumour thrombi.
|
16739096 |
2006 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Stathmin is non-expressed in normal tissues, but stathmin gene is expressed at high levels in many human malignancies and the relationships between the levels of this gene expression in tumors and prognosis of the patients have been addressed.
|
18054374 |
2008 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Stathmin (Oncoprotein18), a ubiquitous and highly conserved 19-kDa cytosolic phosphoprotein, has been reported to play a critical role in mitosis and possibly other cellular processes, which is associated with tumor carcinogenesis and development.
|
19034510 |
2009 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
STMN1 overexpression further identified subgroups of HCC patients with higher tumor recurrence and worse prognosis among HCC patients with early tumor stage (T1) or intermediate histological grades (G2 and G3), both of whom represent the majority of HCC patients receiving primary curative hepatectomy.
|
20232364 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
STMN1-positive tumors were more likely to be found in old age group and associated with p53 nuclear expression.
|
22470493 |
2012 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Stathmin is overexpressed in many human cancers and has a significant relationship with clinical characteristics such as grade, tumor size and prognosis.
|
23229199 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Stathmin suppression did not influence neuroblastoma cell engraftment or tumor growth.
|
23396365 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
STMN1 is a target of microRNA-9, and microRNA-9 could modulate cell proliferation, VM and tumor volume growth through controlling STMN1 expression.
|
24043603 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Stathmin has been investigated as a tumor biomarker because it appear to be associated with tumorigenesis; however, the effect of stathmin in lung adenocarcinoma (LAC) remains poorly understood.
|
27494889 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
STMN1 expression was significantly associated with prognosis and tumour differentiation in ESCC, indicating that STMN1 expression is an independent prognostic factor for ESCC and could be a potential biomarker.
|
29039594 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
A high mRNA level of STMN1 was found in the tumor tissue of gastric adenocarcinoma compared to non-tumor tissue (p<0.05).
|
25075050 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
A series of other endocrine tissues and tumors (n = 70) were also examined for stathmin expression.
|
18461287 |
2008 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Analyses included mutational profiling using the OncoCarta Panel version 1.0 and immunohistochemical expression of the tumor suppressor gene PTEN (phosphatase and tensin homologue) and stathmin, a marker of PI3K activation.
|
24166148 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
As pheochromocytomas are well-differentiated tumors of neural origin, it is not unexpected that stathmin mRNA is overexpressed in these tumors.
|
9678541 |
1998 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Assessment of tau and stathmin protein expression should be considered to select patients before intravesical taxane based chemotherapy for nonmuscle invasive, bacillus Calmette-Guérin refractory bladder cancer since those who have tumors with low tau/stathmin protein expression show a better response to therapy.
|
21944130 |
2011 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Both stathmin and stathmin-like 3 (SCLIP) were overexpressed in adenocarcinoma as well as squamous cell carcinoma (SCC) tissues and induced tumor cell proliferation, migration, and matrix invasion in respective cell lines.
|
19258502 |
2009 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
By contrast, the intratumor T-regulatory and MDSC levels significantly correlated with progression-free and overall survival, the PD-1<sup>+</sup>/LAG-3<sup>+</sup>/TIM-3<sup>+</sup> CD4<sup>+</sup> tumor-infiltrating lymphocytes correlated with overall survival.
|
31078776 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Downregulation of stathmin 1 in human gallbladder carcinoma inhibits tumor growth in vitro and in vivo.
|
27349455 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Esophageal adenocarcinoma cells stably transfected with STMN-1 shRNA significantly reduced tumor xenografts volume in vivo.
|
24433541 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Experimental therapy on the nude mice model bearing subcutaneous tumor of SGC-7901 cells showed that local administration of STMN1 shRNA effectively regressed the pre-established tumors.
|
24720379 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Finally, stathmin expression in a mesothelioma tumor was confirmed by immunohistochemistry.
|
17352214 |
2007 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Furthermore, the association of high Stathmin 1 expression with poor survival was significant even for sub-group analyses of different tumor types, ethnicities, methods used to calculate HRs, detected methods, and analysis types.
|
30278466 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
High tumor expression of STMN1 was significantly associated with the presence of metastases (P=0.028), Enneking surgical stage (P=0.030), tumor response to chemotherapy (P=0.011), and the site of tumor origin (P=0.023).
|
30169496 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
High stathmin immunostaining score in the EC was positively correlated with tumor differentiation, Tumor invasion, Lymph node metastases, and TNM stage.
|
24870766 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
High STMN1 immunoexpression was significantly associated with tumor depth, lymph node metastasis, lymphatic invasion and venous invasion.
|
28350065 |
2017 |